Match!

Impact of oncogenic pathways on evasion of antitumour immune responses

Published on Mar 1, 2018in Nature Reviews Cancer51.848
· DOI :10.1038/nrc.2017.117
Stefani Spranger27
Estimated H-index: 27
,
Thomas F. Gajewski81
Estimated H-index: 81
Sources
Abstract
This Review describes tumour cell-intrinsic oncogenic pathways implicated in tumour immune evasion and highlights the potential for targeting these pathways to overcome resistance to immunotherapy in various cancer types.
  • References (91)
  • Citations (89)
📖 Papers frequently viewed together
201543.07Nature
698 Citations
44 Authors (Weiyi Peng, ..., Patrick Hwu)
335 Citations
201443.07Nature
26 Authors (Paul C. Tumeh, ..., Antoni Ribas)
2,145 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References91
Newest
#1Glenn R. BantugH-Index: 10
#2Lorenzo GalluzziH-Index: 94
Last. Christoph HessH-Index: 31
view all 4 authors...
Here, the authors introduce the idea that a spectrum of metabolic states of immune cells can provide a basis for categorizing human diseases. They explore the metabolic and interlinked signalling requirements of T cells responding to acute infection and how metabolic reprogramming of T cells is linked to disease.
65 CitationsSource
#1Jonathan T. Goldstein (Broad Institute)H-Index: 2
#2Ashton C. Berger (Broad Institute)H-Index: 20
Last. Craig A. Strathdee (Broad Institute)H-Index: 3
view all 9 authors...
The PPARG gene encoding the nuclear receptor PPAR-gamma is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the RXRA gene which encodes the heterodimeric partner of PPAR-gamma. Here we show that activating alterations of PPARG or RXRA lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer ...
16 CitationsSource
#1Antoni Ribas (UCLA: University of California, Los Angeles)H-Index: 100
#2Reinhard DummerH-Index: 98
Last. Georgina V. Long (USYD: University of Sydney)H-Index: 73
view all 20 authors...
Summary Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well tolerated, with fatigue, fevers, and chills as the most common adverse events. No dose-limiting toxicities occurr...
279 CitationsSource
#1Mark YarchoanH-Index: 17
#2Burles A. JohnsonH-Index: 4
Last. Elizabeth M. JaffeeH-Index: 56
view all 5 authors...
Nature Reviews Cancer 17, 209–222 (2017) In the legend of Figure 2 of this article there was an error in the formula for the objective response rate (ORR). The formula should read ORR (%) = 8 x ln(x) + 9. This has now been corrected in the online version.
25 CitationsSource
#1Alejandro Jiménez-Sánchez (University of Cambridge)H-Index: 3
#2Danish Memon (University of Cambridge)H-Index: 5
Last. Martin L. Miller (University of Cambridge)H-Index: 21
view all 19 authors...
Summary We present an exceptional case of a patient with high-grade serous ovarian cancer, treated with multiple chemotherapy regimens, who exhibited regression of some metastatic lesions with concomitant progression of other lesions during a treatment-free period. Using immunogenomic approaches, we found that progressing metastases were characterized by immune cell exclusion, whereas regressing and stable metastases were infiltrated by CD8 + and CD4 + T cells and exhibited oligoclonal expansion...
95 CitationsSource
#1Meng Michelle Xu (U of C: University of Chicago)H-Index: 5
#2Yang Pu (UTSW: University of Texas Southwestern Medical Center)H-Index: 5
Last. Yang-Xin Fu (UTSW: University of Texas Southwestern Medical Center)H-Index: 74
view all 12 authors...
Summary Inhibition of cytosolic DNA sensing represents a strategy that tumor cells use for immune evasion, but the underlying mechanisms are unclear. Here we have shown that CD47-signal regulatory protein α (SIRPα) axis dictates the fate of ingested DNA in DCs for immune evasion. Although macrophages were more potent in uptaking tumor DNA, increase of DNA sensing by blocking the interaction of SIRPα with CD47 preferentially occurred in dendritic cells (DCs) but not in macrophages. Mechanisticall...
43 CitationsSource
#1Mark Ayers (MSD: Merck & Co.)H-Index: 13
#2Jared Lunceford (MSD: Merck & Co.)H-Index: 23
Last. Terrill K. McClanahan (MSD: Merck & Co.)H-Index: 52
view all 15 authors...
Abstract Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant...
351 CitationsSource
#1Dung T. Le (Johns Hopkins University)H-Index: 23
#2Jennifer N. Durham (Johns Hopkins University)H-Index: 4
Last. Luis A. Diaz (Johns Hopkins University)H-Index: 92
view all 46 authors...
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1). We have now expanded this study to evaluate the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types. Objective radiogra...
995 CitationsSource
#1Jiqing Sai (Vandy: Vanderbilt University)H-Index: 16
#2Philip Owens (Vandy: Vanderbilt University)H-Index: 5
Last. Ann Richmond (Vandy: Vanderbilt University)H-Index: 62
view all 17 authors...
Purpose: Metastatic breast cancers continue to elude current therapeutic strategies, including those utilizing PI3K inhibitors. Given the prominent role of PI3Kα,β in tumor growth and PI3Kγ,δ in immune cell function, we sought to determine whether PI3K inhibition altered antitumor immunity. Experimental Design: The effect of PI3K inhibition on tumor growth, metastasis, and antitumor immune response was characterized in mouse models utilizing orthotopic implants of 4T1 or PyMT mammary tumors into...
13 CitationsSource
#1Daniela Massi (UniFI: University of Florence)H-Index: 45
#2Emanuella Romano (PSL Research University)H-Index: 19
Last. Mario MandalàH-Index: 44
view all 11 authors...
Abstract Background The activation of oncogenic Wnt/β-catenin pathway in melanoma contributes to a lack of T-cell infiltration. Whether baseline β-catenin expression in the context of tumour-infiltrating lymphocytes (TILs) and programmed death ligand-1 (PD-L1) overexpression correlates with prognosis of metastatic melanoma patients (MMPs) treated with mitogen-activated protein kinase, MAPK inhibitor (MAPKi) monotherapy, however, has not been fully clarified. Patients and methods Sixty-four pre-t...
16 CitationsSource
Cited By89
Newest
Chemoimmunotherapy (CIT) is the standard of care in B-cell malignancies. It is relying on synergistic effects of alkylating chemotherapy and monoclonal antibodies via secretory crosstalk with effector macrophages. Here, we observed that loss of p53 function mediates resistance to CIT by suppressing macrophage phagocytic function. Loss of p53 leads to an upregulation of PDL1 and an increased formation of extracellular vesicles (EVs). EVs directly inhibit macrophage phagocytosis by PDL1 surface ex...
Source
#1Daria S. Chulpanova (Kazan: Kazan Federal University)H-Index: 3
#2Kristina V. Kitaeva (Kazan: Kazan Federal University)H-Index: 3
Last. Valeriya V. Solovyeva (Kazan: Kazan Federal University)H-Index: 4
view all 5 authors...
Cytokine-based immunotherapy is a promising field in the cancer treatment, since cytokines, as proteins of the immune system, are able to modulate the host immune response towards cancer cell, as well as directly induce tumor cell death. Since a low dose monotherapy with some cytokines has no significant therapeutic results and a high dose treatment leads to a number of side effects caused by the pleiotropic effect of cytokines, the problem of understanding the influence of cytokines on the immu...
Source
#1John B. A. G. Haanen (NKI-AVL: Netherlands Cancer Institute)H-Index: 59
#2Christian U. Blank (NKI-AVL: Netherlands Cancer Institute)H-Index: 50
: Cancer immunotherapy utilizing immune checkpoint inhibitors, has become mainstay for a growing number of cancer types. However, in general, the objective response rate and survival is only improved in a minority of cancer patients. Many of the biomarkers to select patients that either benefit or do not, have next to being predictive also prognostic value, are continuous instead of categorical, and are therefore difficult to use in daily practice. Currently, PD-L1 by immunohistochemical stainin...
1 CitationsSource
#1Shuangshuang Mao (Peking Union Medical College)H-Index: 4
#2Yuan Li (Peking Union Medical College)H-Index: 6
Last. Sufei Zheng (Peking Union Medical College)H-Index: 1
view all 14 authors...
PURPOSE Lung adenocarcinoma (LUAD) is the predominant subtype of lung cancer, with increasing evidence showing clinical benefits of immunotherapy. However, a lack of integrated profiles of complex LUAD immune microenvironments hampers the application of immunotherapy, resulting in limited eligible patient populations as well as drug resistance problems. Here, we aimed to systematically profile the immune signatures of LUADs and to assess the role of the immune microenvironment in patient outcome...
Source
: Therapeutic monoclonal antibodies for the treatment of cancer came of age in 1997, with the approval of anti-CD20 Rituximab. Since then, a wide variety of antibodies have been developed with many different formats and mechanisms of action. Among these, antibodies blocking immune checkpoint inhibitors (ICI) have revolutionized the field, based on the novelty of their concept and their demonstrated efficacy in several types of cancer otherwise lacking effective immunotherapy approaches. ICI are ...
Source
#1Lu Ji (SJTU: Shanghai Jiao Tong University)
#2Wei Qian (SJTU: Shanghai Jiao Tong University)H-Index: 2
Last. Wei-Qiang Gao (SJTU: Shanghai Jiao Tong University)H-Index: 40
view all 9 authors...
Dysregulation of Wnt/β-catenin signaling is frequently observed in human gastric cancer. Elucidation of the tumor immune microenvironment is essential for understanding tumorigenesis and for the development of immunotherapeutic strategies. However, it remains unclear how β-catenin signaling regulates the tumor immune microenvironment in the stomach. Here we identify CCL28 as a direct transcriptional target gene of β-catenin/T cell factor (TCF). Protein levels of β-catenin and CCL28 positively co...
Source
: Nanoparticles (NPs) have been increasingly studied for radiosensitization. The principle of NPs radio-enhancement is to use high-atomic number NPs (e.g. gold, hafnium, bismuth and gadolinium) or deliver radiosensitizing substances, such as cisplatin and selenium. Nowadays, cancer immunotherapy is emerged as a promising treatment and immune checkpoint regulation has a potential property to improve clinical outcomes in cancer immunotherapy. Furthermore, NPs have been served as an ideal platform ...
Source
#1Zheng Zhong (NUS: National University of Singapore)H-Index: 1
#2Jia Yu (NUS: National University of Singapore)H-Index: 5
Last. Babita Madan (NUS: National University of Singapore)H-Index: 21
view all 4 authors...
Since the discovery of the first mammalian Wnt proto-oncogene in virus-induced mouse mammary tumors almost four decades ago, Wnt signaling pathway and its involvement in cancers have been extensively investigated. Activation of this evolutionarily conserved pathway promotes cancer development via diverse mechanisms. Cancer is a complex disease and one outstanding conceptual framework for understanding its biology is the "Hallmarks of Cancer". In this review, we focus on the involvement of Wnt si...
Source
#1Shamik Mitra (Lund University)H-Index: 2
#2Martin Lauss (Lund University)H-Index: 22
Last. Johan Staaf (Lund University)H-Index: 37
view all 14 authors...
The presence of immune cells in the tumor microenvironment has been associated with response to immunotherapies across several cancer types, including melanoma. Despite its therapeutic relevance, characterization of the melanoma immune microenvironments remains insufficiently explored. To distinguish the immune microenvironment in a cohort of 180 metastatic melanoma clinical specimens, we developed a method using promoter CpG methylation of immune cell type-specific genes extracted from genome-w...
1 CitationsSource
#1Alberto PucciniH-Index: 6
#2Francesca Battaglin (SC: University of Southern California)H-Index: 7
Last. Mohamed E. SalemH-Index: 6
view all 5 authors...
In the last few years, the unprecedented results of immune checkpoint inhibitors have led to a paradigm shift in clinical practice for the treatment of several cancer types. However, the vast majority of patients with gastrointestinal cancer do not benefit from immunotherapy. To date, microsatellite instability high and DNA mismatch repair deficiency are the only robust predictive biomarkers of response to immune checkpoint inhibitors. Unfortunately, these patients comprise only 5%–10% of all ga...
1 CitationsSource